AZ's Farxiga Fillip As Drug Reduces Renal Disease Risk In Type 2 Diabetics
AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.
You may also be interested in...
The UK pharma said the FDA had issued a complete response letter, declining its application for using Farxiga in the new T1D indication. Analysts suspect worries over diabetic ketoacidosis risk lie behind the rejection.
Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.
The German major believes its drug will remain the biggest-selling SGLT-2 inhibitor boosted by expanded heart and renal disease approvals.